| 49 | 0 | 55 |
| 下载次数 | 被引频次 | 阅读次数 |
刘华教授认为肺癌转移具有邪伏隐匿、传变迅速、病势凶险等临床特点,其病理因素不离毒、痰、瘀、虚,病涉多脏,病机复杂,肺癌转移期的核心病机为癌毒传舍,正虚毒伏是肺癌空窗期癌毒形成的前提条件,毒锢正竭是肺癌终期癌毒传舍难控的最终结果,临证主张运用“截断扭转”法分阶段截断病机传变扭转病势。空窗期侧重扶正解毒,防毒内伏截断癌毒复萌,扶正亦可解毒,突出补肺健脾益肾;转移期强调攻伐癌毒、化痰祛瘀、扶正安虚截断癌毒传舍,擅用虫类药攻毒;终末期温补脾肾,保胃气贯穿始终,力图扭转殆势。
Abstract:Professor LIU Hua considers that lung cancer metastasis exhibits clinical characteristics such as hidden pathogenic factors, rapid progression, and severe dangerous disease conditions. Its pathological mechanisms involve toxins, phlegm, blood stasis, and deficiency, affecting multiple organs with complex pathogenesis. The core mechanism during metastasis is the dissemination of cancer toxins, where "deficiency and toxin concealment" serves as the prerequisite for toxin formation in the asymptomatic phase. The ultimate outcome of "toxin stagnation and depletion of vital energy" leads to uncontrollable toxin dissemination in the terminal stage. Clinically, he advocates the "truncated and torsinal" method to disrupt pathogenesis and reverse disease progression in stages. In the asymptomatic phase, emphasis is placed on tonifying the body, detoxifying, and preventing toxin concealment to block toxin recurrence-tonification can also detoxify, highlighting the importance of nourishing the lungs, strengthening the spleen, and benefiting the kidneys. During metastasis, the focus is on attacking cancer toxins, resolving phlegm, eliminating blood stasis, and tonifying the body to intercept toxin dissemination, with adept use of insect-based medicines for toxin removal. In the terminal stage, warming and tonifying the spleen and kidneys, while preserving stomach qi, is maintained throughout to strive for disease reversal.
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA:a cancer journal for clinicians,2024,74(3):229-263.
[2] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[3] CHAFFER CL,WEINBERG RA.A perspective on cancer cell metastasis[J].Science,2011,(331):1559-1564.
[4] RUSSO M,CHEN M,MARIELLA E,et al.Cancer Drug-tolerant persister cells:From Biological Questions to Clinical Opportunities[J].Nature Reviews Cancer,2024,24(10):694–717.
[5] RAO Z,WANG Z,DENG H,et al.Role of Traditional Chinese Medicine in Lung Cancer Management:A Review[J].The American Journal of Chinese Medicine,2025:1-21.
[6] 贝润浦.论姜春华处理病证关系的临床特色[J].中国医药学报,1989(2):47-50.
[7] 徐力,鹿竞文.论恶性肿瘤截断疗法[J].中国中医药信息杂志,2013,20(4):92-94.
[8] 李杳瑶,刘华,孙铜林,等.基于数据挖掘探析刘华教授治疗非小细胞肺癌的学术思想[J].湖南中医药大学学报,2023,43(2):327-331.
[9] 赵智强,李嘉.略论周仲瑛教授的“癌毒”学说及其临床运用[J].新中医,1998(10):7-9.
[10] 范洪桥,刘丽芳,熊家青,等.从中医学角度探讨护场与恶性肿瘤的传舍[J].辽宁中医杂志,2019,46(9):1853-1854.
[11] 钟佳,刘华,王理槐.基于“癌毒传舍”理论防治肺癌转移[J].湖南中医药大学学报,2021,41(12):1950-1953.
基本信息:
DOI:10.13913/j.cnki.41-1110/r.2026.01.010
中图分类号:R249;R273
引用信息:
[1]姚巧巧,孙铜林,刘华.刘华运用截断扭转法防治肺癌转移经验[J].国医论坛,2026,41(01):59-62.DOI:10.13913/j.cnki.41-1110/r.2026.01.010.
基金信息:
湖南省中医药管理局基金项目(B2024053); 湖南省临床医学研究中心(基地)项目(2021SK4023)
2026-01-20
2026-01-20